Conditioned immunomodulation: Investigations of the role of endogenous activity at μ, κ, and δ opioid receptor subtypes

Journal of Neuroimmunology

Volumn 79, Issue 2, 1997, Pages 101-112

  Perez, Lynn ^a   Lysle, Donald T ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Conditioning; Interferon; Mitogen; Neuroimmunomodulation; Opioid; Rat

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONDITIONING; CONTROLLED STUDY; DRUG RECEPTOR BINDING; IMMUNOMODULATION; IMMUNOSTIMULATION; KILLER CELL; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL; STIMULUS RESPONSE;

ANIMALS; AVOIDANCE LEARNING; CELL DIVISION; CONDITIONING, CLASSICAL; ELECTROSHOCK; IMMUNE SYSTEM; KILLER CELLS; LIPOPOLYSACCHARIDES; MALE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, INBRED LEW; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SPLEEN;

EID: 0030780412     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00106-9     Document Type: Article

References (47)

1. Ader R., Cohen N. Behaviorally conditioned immunosuppression. Psychosom. Med. 37:1975;333-340.
2. Ayers E.A., Davis P., Burks T.F. In vivo and in vitro investigation of naltrindole, a δ-opioid antagonist. Proc. West. Pharmacol. Soc. 33:1990;55-63.
3. Bartop R.W., Luckhurst E., Lazarus L., Kiloh L.G., Penny R. Depressed lymphocyte function after bereavement. Lancet. 1:1977;834-836.
4. Buckingham J.C., Cooper T.A. Effects of naloxone on hypothalamo-pituitary-adrenocortical activity in the rat. Neuroendocrinol. 42:1986;421-426.
5. Buckingham J.C., Cooper T.A. Interrelationships of opioidergic and adrenergic mechanisms controlling secretion of corticotrophin releasing factor in the rat. Neuroendocrinol. 46:1987;199-206.
6. Carr D.J.J. The role of endogenous opioids and their receptors in the immune system. Proc. Soc. Exp. Biol. Med. 198:1991;710-720.
7. Coussons M.E., Dykstra L.A., Lysle D.T. Pavlovian conditioning of morphine-induced alterations of immune status. J. Neuroimmunol. 39:1992;219-230.
8. 5]enkephalin in the rat. J. Pharm. Exp. Ther. 259:1991;725-731.
9. Endoh T., Matsuura H., Tanaka C., Nagase H. Nor-binaltorphimine: A potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch. Int. Pharmacodyn. Ther. 316:1992;30-42.
10. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T. Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats. J. Pharm. Exp. Ther. 276:1996;626-636.
11. Jackson H.C., Ripley T.L., Nutt D.J. Exploring δ-receptor function using the selective opioid antagonist naltrindole. Neuropharmacol. 28(12):1989;1427-1430.
12. Jones D.N., Holtzman S.G. Long term kappa-opioid receptor blockade following nor- binaltorphimine. Eur. J. Pharm. 215:1992;345-348.
13. Joseph S.A., Pilcher W.H., Knigge K.M. Anatomy of the corticotropin-releasing factor and opiomelanocortin systems of the brain. Fed. Proc. 44:1985;100-107.
14. Kitchen I., Pinker S.R. Antagonism of swim-stress-induced antinociception by the δ-opioid receptor antagonist naltrindole in adult and young rats. Br. J. Pharmacol. 100:1990;685-688.
15. Keller S.E., Wiess J.M., Schleifer S.J., Miller N.E., Stein M. Suppression of immunity by stress: Effect of a graded series of stressors on lymphocyte stimulation in the rat. Science. 213:1981;1397-1400.
16. Keller S.E., Wiess J.M., Schleifer S.J., Miller N.E., Stein M. Stress-induced suppression of immunity in adrenalectomized rats. Science. 221:1983;1301-1304.
17. Kiecolt-Glaser J.K., Fisher L.D., Ogrocki P., Stout J.C., Speicher C.E., Glaser R. Marital quality, marital disruption, and immune function. Psychosom. Med. 49(1):1987;13-34.
18. Laudenslager M.L., Fleshner M., Hofstadter P., Held P.E., Simons L., Maier S.F. Suppression of specific antibody production by inescapable shock: Stability under varying conditions. Brain Behav. Immun. 2:1988;92-101.
19. Laudenslager M.L., Ryan S.M., Drugan R.C., Hyson R.L., Maier S.F. Coping and immunosuppression: Inescapable but not escapable shock suppresses lymphocyte proliferation. Science. 221:1983;568-570.
20. Lewis J.W., Shavit Y., Terman G.W., Nelson L.R., Gale R.P., Liebeskind J.C. Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. Peptides. 4:1983;635-638.
21. Ling G.S.F., Simantov R., Clark J.A., Pasternak G.W. Naloxonazine actions in vivo. Eur. J. Pharm. 129:1986;33-38.
22. Lockwood L.L., Silbert L.H., Fleshner M., Laudenslager M.L., Watkins L.R., Maier S.F. Morphine-induced decreases in vivo antibody responses. Brain Behav. Immun. 8:1994;24-36.
23. Luecken L.J., Lysle D.T. Evidence for the involvement of β-adrenergic receptors in conditioned immunomodulation. J. Neuroimmunol. 38:1992;209-220.
24. Lysle D.T., Coussons M.E., Watts V.J., Bennett E.H., Dykstra L.A. Morphine-induced alterations of immune status: Dose dependency, compartment specificity and antagonism by naltrexone. J. Pharm. Exp. Ther. 265(3):1993;1071-1078.
25. Lysle D.T., Cunnick J.E., Fowler H., Rabin B.S. Pavlovian conditioning of shock-induced suppression of lymphocyte reactivity: Acquisition, extinction, and preexposure effects. Life Sci. 42:1988;2185-2194.
26. Lysle D.T., Cunnick J.E., Kucinski B.J., Fowler H., Rabin B.S. Characterization of immune alterations induced by a conditioned aversive stimulus. Psychobiol. 18:1990;220-226.
27. Lysle D.T., Cunnick J.E., Maslonek K.A. Pharmacological manipulation of immune alterations induced by an aversive conditioned stimulus: Evidence for a β-adrenergic receptor-mediated Pavlovian conditioning process. Behav. Neurosci. 105:1991;443-449.
28. Lysle D.T., Hoffman K.E., Dykstra L.A. Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status. J. Pharm. Exp. Ther. 277(3):1996;1540-1553.
29. Lysle D.T., Luecken L.J., Maslonek K.A. Modulation of immune status by a conditioned aversive stimulus: Evidence for the involvement of endogenous opioids. Brain Behav. Immun. 6:1992;179-188.
30. Lysle D.T., Lyte M., Fowler H., Rabin B.S. Shock-induced modulation of lymphocyte reactivity: Suppression, habituation, and recovery. Life Sci. 41:1987;1805-1814.
31. MacQueen G.M., Siegel S. Conditional immunomodulation following training with cyclophosphamide. Behav. Neurosci. 103:1989;638-647.
32. Magnan J., Paterson S.J., Tavani A., Kosterlitz H.W. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Arch. Pharmacol. 319:1982;197-205.
33. Manuck S.B., Cohen S., Rabin B.S., Muldoon M.F., Bachen E.A. Individual differences in cellular immune response to stress. Psychol. Sci. 2(2):1991;111-115.
34. Moynihan J.A., Ader R., Grota L.J., Schachtman T.R., Cohen N. The effects of stress on the development of immunological memory following low-dose antigen priming in mice. Brain Behav. Immun. 4:1990;1-12.
35. Paronis C.A., Waddell A.B., Holtzman S.G. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine. Pharm. Biochem. Behav. 46:1993;813-817.
36. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, San Diego, CA.
37. Perez L., Lysle D.T. Corticotropin-releasing hormone is involved in conditioned stimulus-induced reduction of natural killer cell activity but not in conditioned alterations in cytokine production or proliferation responses. J. Neuroimmunol. 63:1995;1-8.
38. Pross H.F., Maroun J.A. The standardization of NK cell assays for use in studies of biological response modifiers. J. Immunol. Methods. 68:1984;235-249.
39. Schneider, G.M., Lysle, D.T., 1996. Effects of centrally administered Opioid Agonists on Macrophage Nitric Oxide Production and Splenic Lymphocyte Proliferation. In: Friedman, H., Eisenstein, T.K., Madden, J., Sharp, B.M. (Eds.), AIDS, Drugs of Abuse, and the Neuroimmune Axis. Plenum Press, New York, pp. 81-88.
40. Shavit Y., Depaulis A., Martin F.C., Terman G.W., Pechnick R.N., Zane C.J., Gale R.P., Liebeskind J.C. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc. Natl. Acad. Sci. USA. 83:1986;7114-7117.
41. Shavit Y., Lewis J.W., Terman G.W., Gale R.P., Liebeskind J.C. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science. 223:1984;188-190.
42. Simone D.A., Bodnar R.J., Portzline T., Pasternak G.W. Antagonism of morphine analgesia by intracerebroventricular naloxonazine. Pharm. Biochem. Behav. 24:1986;1721-1727.
43. Sofuoglu M., Portoghese P.S., Takemori A.E. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: Evidence for delta receptor subtypes. J. Pharm. Exp. Ther. 257:1991;676-680.
44. Solvason H.B., Hiramoto R.N., Ghanta V.K. Naltrexone blocks the expression of the conditioned elevation of natural killer cell activity in BALB/c mice. Brain Behav. Immun. 3:1989;247-262.
45. Takemori A.E., Ho B.Y., Naeseth J.S., Portoghese P.S. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharm. Exp. Ther. 246:1988;255-258.
46. Tortella F.C., Echevarria E., Lipkowski A.W., Takemori A.E., Portoghese P.S., Holaday J.W. Selective kappa antagonist properties of nor-binaltorphimine in the rat MES model. Life Sci. 44:1989;661-665.
47. Weber R.J., Pert A. The periaqueductal gray matter mediates opiate-induced immunosuppression. Science. 245:1989;188-190.